Leukemia research · 2026
Efficacy and safety of BCMA-directed bispecific antibodies in relapsed and/or refractory systemic AL amyloidosis: A systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Shuhui, Luo Jiayi, Yu Guopan, Zhu Yangmin
Аннотация
BACKGROUND: Patients with relapsed/refractory (R/R) systemic light chain (AL) amyloidosis, particularly after daratumumab failure, face limited treatment options and challenging outcomes. B-cell maturation antigen (BCMA)-directed bispecific antibodies (BsAbs) have emerged as a potent strategy in multiple myeloma, yet their collective performance in AL amyloidosis remains to be systematically evaluated.
METHODS: Following PRISMA guidelines, we analyzed 8 independent cohorts (80 patients) treated with teclistamab or elranatamab. A random-effects model with Hartung-Knapp adjustment was employed to pool outcomes.
RESULTS: The pooled hematologic overall response rate (ORR) was 91% (95% CI: 87%-93%), with a deep hematologic complete response (hCR) rate of 64% (95% CI: 42%-82%). Rapid organ recovery was a hallmark of treatment: the pooled cardiac and renal response rates reached 59% (95% CI: 32%-82%) and 34% (95% CI: 14%-62%), cytokine release syndrome (CRS) was frequent but manageable (60%; 95% CI: 53%-67%), while immune effector cell-associated neurotoxicity syndrome (ICANS) remained rare (7%). However, Grade ≥ 3 infections were observed in 25% (95% CI: 15%-40%) of patients, potentially associated with T-cell dysfunction and therapy-induced hypogammaglobulinemia.
CONCLUSION: BCMA-directed BsAbs demonstrate potent hematologic efficacy in R/R AL, achieving deep and rapid light-chain clearance. This hematologic response translates into significant organ functional recovery. However, the high incidence of severe infections necessitates proactive antimicrobial prophylaxis, dose optimization, and immunoglobulin supplementation.
METHODS: Following PRISMA guidelines, we analyzed 8 independent cohorts (80 patients) treated with teclistamab or elranatamab. A random-effects model with Hartung-Knapp adjustment was employed to pool outcomes.
RESULTS: The pooled hematologic overall response rate (ORR) was 91% (95% CI: 87%-93%), with a deep hematologic complete response (hCR) rate of 64% (95% CI: 42%-82%). Rapid organ recovery was a hallmark of treatment: the pooled cardiac and renal response rates reached 59% (95% CI: 32%-82%) and 34% (95% CI: 14%-62%), cytokine release syndrome (CRS) was frequent but manageable (60%; 95% CI: 53%-67%), while immune effector cell-associated neurotoxicity syndrome (ICANS) remained rare (7%). However, Grade ≥ 3 infections were observed in 25% (95% CI: 15%-40%) of patients, potentially associated with T-cell dysfunction and therapy-induced hypogammaglobulinemia.
CONCLUSION: BCMA-directed BsAbs demonstrate potent hematologic efficacy in R/R AL, achieving deep and rapid light-chain clearance. This hematologic response translates into significant organ functional recovery. However, the high incidence of severe infections necessitates proactive antimicrobial prophylaxis, dose optimization, and immunoglobulin supplementation.